Back to Farallon Capital Management, L.L.C. Farallon Capital Management, L.L.C.

AXSMAXSM

Showing 8 of 16 quarters

Position history for Farallon Capital Management, L.L.C.Farallon Capital Management, L.L.C.'s holdings in Axsome Therapeutics, Inc.

No. Farallon Capital Management exited its AXSM (Axsome Therapeutics) position in Q2 2026. Its Q1 2026 13F listed 4,000 shares worth $676,080. Farallon Capital Management first reported AXSM in Q3 2019 and held it in 14 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$359,480

Total Shares Change

-4,000

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$244.77
0
2026-Q1
Unchanged
4,000
0.0%
$676,0800.0%$169.02
0
2025-Q4
Unchanged
4,000
0.0%
$730,5600.0%$182.64
0
2025-Q3
Unchanged
4,000
0.0%
$485,8000.0%$121.45
0
2025-Q2
Unchanged
4,000
0.0%
$417,5600.0%$104.39
0
2025-Q1
Unchanged
4,000
0.0%
$466,5200.0%$116.63
0
2024-Q4
Unchanged
4,000
0.0%
$338,4400.0%$84.61
0
2024-Q3
Unchanged
4,000
0.0%
$359,4800.0%$89.87
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used